Basiliximab
Modify Date: 2024-01-02 08:28:44
Basiliximab structure
|
Common Name | Basiliximab | ||
|---|---|---|---|---|
| CAS Number | 179045-86-4 | Molecular Weight | N/A | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | N/A | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of BasiliximabBasiliximab (CHI 621) is a recombinant chimeric murine/human IgG1 monoclonal anti-interleukin-2 receptor antibody. Basiliximab can be used for the research of renal transplantation[1]. |
| Name | Unii-9927mt646m |
|---|
| Description | Basiliximab (CHI 621) is a recombinant chimeric murine/human IgG1 monoclonal anti-interleukin-2 receptor antibody. Basiliximab can be used for the research of renal transplantation[1]. |
|---|---|
| Related Catalog | |
| Target |
Interleukin-2 receptor[1] |
| In Vitro | Basiliximab specifically inhibits T lymphocyte proliferation by binding to the IL-2Rα[1]. Basiliximab binds only to activated lymphocytes and macrophages/monocytes[3]. Basiliximab does not affect resting T lymphocytes that do not express IL-2Rα[3]. |
| In Vivo | Basiliximab (CHI 621) (0.07 mg/rat; i.v.; once) decreases total placental natural killer cells in reduced uterine perfusion pressure (RUPP) rats[2]. Animal Model: Timed-pregnant Sprague Dawley (SD) rats, reduced uterine perfusion pressure (RUPP) rat model of placental ischemia[2] Dosage: 0.07 mg/rat Administration: IV infusion, once Result: Decreased total placental natural killer cells. Had no effect to lower MAP or improve pup weight and placental weight. |
| References |
| No Any Chemical & Physical Properties |